Archer Investment Corporation’s Lineage Cell Therapeutics LCTX Stock Holding History

Archer Investment Corporation’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,000	Closed	-$1.41K	–	1032
2023 Q2	$1.41K	Hold	1,000	–	–	﹤0.01%	884
2023 Q1	$1.5K	Hold	1,000	–	–	﹤0.01%	754
2022 Q4	$1.17K	Hold	1,000	–	–	﹤0.01%	744
2022 Q3	$1.13K	Hold	1,000	–	–	﹤0.01%	721
2022 Q2	$1.58K	Hold	1,000	–	–	﹤0.01%	702
2022 Q1	$1.54K	Hold	1,000	–	–	﹤0.01%	715
2021 Q4	$2.45K	Hold	1,000	–	–	﹤0.01%	676
2021 Q3	$2.52K	Hold	1,000	–	–	﹤0.01%	636
2021 Q2	$2.85K	Hold	1,000	–	–	﹤0.01%	522
2021 Q1	$2.35K	Hold	1,000	–	–	﹤0.01%	668
2020 Q4	$1.76K	Hold	1,000	–	–	﹤0.01%	639
2020 Q3	$937	Hold	1,000	–	–	﹤0.01%	604
2020 Q2	$870	Hold	1,000	–	–	﹤0.01%	608
2020 Q1	$1K	Hold	1,000	–	–	﹤0.01%	564
2019 Q4	$2K	Hold	1,000	–	–	﹤0.01%	558
2019 Q3	$1K	Hold	1,000	–	–	﹤0.01%	473
2019 Q2	$1K	Hold	1,000	–	–	﹤0.01%	462
2019 Q1	$1K	Hold	1,000	–	–	﹤0.01%	475
2018 Q4	$1K	Buy	+1,000	New	+$1.53K	﹤0.01%	444

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Archer Investment Corporation's LCTX Position: Q3 2023 in Review

Archer Investment Corporation sold out of Lineage Cell Therapeutics (LCTX) in Q3 2023, closing a stake of 1,000 shares — an estimated $1.41K sold.

Archer Investment Corporation first reported a position in LCTX in Q4 2018 and held it in 19 quarters. The position peaked at $2.85K in Q2 2021. 104 funds tracked by Wall St. Rank hold LCTX as of Q3 2023.

Archer Investment Corporation reported no remaining Lineage Cell Therapeutics position as of Q3 2023 after selling out during the quarter.
Archer Investment Corporation sold 1,000 Lineage Cell Therapeutics shares in Q3 2023, an estimated $1.41K.
Archer Investment Corporation first reported a position in Lineage Cell Therapeutics in Q4 2018 and held it in 19 quarters.
Archer Investment Corporation's Lineage Cell Therapeutics position peaked at $2.85K in Q2 2021.
104 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2023.

Based on Archer Investment Corporation's 13F filing for Q3 2023, filed 8 Nov 2023.